Celyad Oncology - ADR
CYAD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.47M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19.47 Million |
|---|---|
| Enterprise Value | $19.74 Million |
| Earnings per Share | $-0.14 |
| Beta | 1.69 |
| Outstanding Shares | 41,429,000 |
Return
| Return on Equity | -253.58% |
|---|---|
| Return on Assets | -136.99% |
| Return on Invested Capital | -809.82% |
Valuation & Multiples
| P/E Ratio | 2.41 |
|---|---|
| PEG | -3.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 102.29 |
| Enterprise Value to EBIT | -1.75 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Celyad Oncology
17 employees
CEO: Filippo Petti
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an a...